Gland Pharma Q1FY22 profit rises 12% on new launches, COVID drugs Remdesivir and Enoxaparin

Gland Pharma Q1FY22 profit rises 12% on new launches, COVID drugs Remdesivir and Enoxaparin Revenue from operations rose 31 percent YoY to Rs 1,153.9 crore in Q1FY22 versus Rs 884.2 crore in Q1FY21.

No comments:

Post a Comment